GenMont Biotech Incorporation

Taiwan Stock Exchange 3164.TW

GenMont Biotech Incorporation EBITDA Margin for the year ending December 31, 2023: 29.53%

GenMont Biotech Incorporation EBITDA Margin is 29.53% for the year ending December 31, 2023, a -5.88% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • GenMont Biotech Incorporation EBITDA Margin for the year ending December 31, 2022 was 31.38%, a -18.44% change year over year.
  • GenMont Biotech Incorporation EBITDA Margin for the year ending December 31, 2021 was 38.47%, a 26.90% change year over year.
  • GenMont Biotech Incorporation EBITDA Margin for the year ending December 31, 2020 was 30.32%, a 7.03% change year over year.
  • GenMont Biotech Incorporation EBITDA Margin for the year ending December 31, 2019 was 28.32%, a -19.99% change year over year.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
SV Wall Street
Taiwan Stock Exchange: 3164.TW

GenMont Biotech Incorporation

CEO Yu Chin Chen
IPO Date Sept. 19, 2008
Location Taiwan
Headquarters No.8, Nanke 7th Road
Employees 147
Sector Consumers Staples
Industries
Personal Care Baby & Childcare Biotechnology Dental Care Frozen Foods Pet Food Pharmaceuticals Vaccines
Description

GenMont Biotech Incorporation engages in the research, development, production, and sale of functional probiotic products in Taiwan. The company also offers probiotics with special functions; and original formula design and manufacturing, and equipment manufacturing services on health care food, as well as cooperates in the research, production, and clinical trial of various products. GenMont Biotech Incorporation was founded in 2000 and is headquartered in Tainan City, Taiwan.

StockViz Staff

February 4, 2025

Any question? Send us an email